



**The CoreAccess Solution contains a comprehensive audit toolset which ensures the integrity of electronic records in accordance with "Best Practice" Corporate Governance and specifically with the United States Food and Drug Administration Board's regulation 21 CFR part 11.**



For further information, please contact:-

Mary Doyle  
TDS Ltd,  
2060 Castle Drive,  
Citywest Business Park  
Naas Road,  
Dublin,  
Ireland.  
Tel: +353 1 4663060  
Email: mary.doyle@tds.ie  
Website: [www.tds.ie](http://www.tds.ie)

**Press Release – 21<sup>st</sup> October 2009**

**Astellas Ireland**

## **Astellas Selects TDS' CoreAccess Pharma Edition**

**Another Leading Pharmaceutical Organisation Selects TDS' CoreAccess Pharma Edition To Cater For Their Extensive Access Control and Security Requirements.**

Astellas was founded in 2005 following the merger of Fujisawa and Yamanouchi and is now one of the top 20 Pharmaceutical companies in the world. Today, Astellas employs around 15,000 worldwide and 470 people in their Irish operations. With three European based manufacturing plants Astellas has greater coverage than ever, two of which are located in Ireland: Dublin based API plant and Kerry based Formulation, Packaging and R&D plant.

The increased onus on Astellas to protect sensitive information was critical to the deployment of the **CoreAccess** Pharma solution. The TDS solution provides full control over who is allowed access through any controlled point at any time of any day, thus ensuring onsite security and safety in an unobtrusive manner. The **CoreAccess** solution provides for the distribution of intelligent Kaba Benzing Access Control terminals across Astellas Kerry based manufacturing plant.

A key requirement for Astellas was to ensure full FDA compliance. The **CoreAccess** Solution contains a comprehensive audit toolset which ensures the integrity of electronic records in accordance with "Best Practice" Corporate Governance and specifically with the United States Food and Drug Administration Board's regulation 21 CFR part 11. This will enable Astellas to comply with federal regulation such as CFR Part 11

In addition **CoreAccess** will help ensure on-site security and safety for all members of staff, contractors and visitors. The latest Kaba Hardware Technology will be deployed working in conjunction with Mifare Technology ensuring a single card solution for Access Control, Time & Attendance & Cashless Catering.

This deployment further strengthens TDS' position as a leading provider of tailored Access Control solutions to the Pharmaceutical sector. Other Pharmaceutical clients include Pfizer, Bausch & Lomb, Braun, Bristol Myers Squibb, DePuy, Eli Lilly, Janssen, Leo Laboratories, Proctor & Gamble, Roche and Wyeth Medica.